POLB
NEUTRALPoolbeg Pharma Chair Increases Stake
The prominent biopharmaceutical company has announced that its Executive Chair has purchased additional shares in the business.
Poolbeg Pharma
3.2000GBX
10.34%
Market Cap
25.39M
Volume
150k
7% of avg
P/E Ratio
-0.03
EPS (TTM)
-1.19
Beta
1.91
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p3.2000p14.0420p
3.2000p
Upcoming Events
POLB
NEUTRALPoolbeg Pharma Receives FDA Orphan Drug Designation for POLB 001
The biopharmaceutical company has received Orphan Drug Designation from the FDA for its POLB 001 drug candidate, which is being developed as a preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome.
POLB
NEUTRALPoolbeg Pharma Releases Annual Report and AGM Notice
The biopharmaceutical company has released its annual report and notice of the upcoming annual general meeting.
POLB
NEUTRALPoolbeg Pharma Raises £150,000 in Oversubscribed Bookbuild Offer
The biopharmaceutical company has conditionally raised £150,000 through an oversubscribed bookbuild offer, with the funds to be used for advancing its clinical pipeline.
POLB
GOODPoolbeg Pharma Increases BookBuild Offer to Raise £150,000
The biopharmaceutical company is increasing its BookBuild Offer to raise £150,000 to fund the advancement of its clinical pipeline, including trials for a cancer immunotherapy and an oral GLP-1 program.
POLB
GOODPoolbeg Pharma Raises £4.7M to Advance Key Clinical Trials
The biopharmaceutical company has raised £4.7 million through a placing and subscription to advance its pipeline, including a Phase 2a trial for its cancer immunotherapy candidate.
POLB
NEUTRALPoolbeg Pharma Announces Retail Offer to Raise up to £100,000
The biopharmaceutical company is offering a retail share offer to raise up to £100,000 from existing shareholders.
POLB
BADPoolbeg Pharma Announces £4.1M Fundraise at Discount
The healthcare company announces a £4.1 million equity raise at a 12% discount, signaling potential challenges.
POLB
BADPoolbeg Pharma Reports Increased Losses as Clinical Programs Advance
The clinical-stage biopharmaceutical company reported increased losses as it advances its drug candidates. Despite progress in key programs, financial metrics show growing cash burn.
POLB
NEUTRALPoolbeg Pharma to Participate in Key Conferences in March and April 2025
The biopharmaceutical company will present at the Master Investor Show, BioTrinity, and participate in a panel discussion at the LSX World Congress in the coming months.